Management

This page includes content on healthcare management, including health system, hospital, department and clinic business management and administration. Areas of focus are on cardiology and radiology department business administration. Subcategories covered in this section include healthcare economics, reimbursement, leadership, mergers and acquisitions, policy and regulations, practice management, quality, staffing, and supply chain.

RSS icon

Medicines Company stops development of investigational cardiovascular medication

After analyzing data from a recent trial, the Medicines Company announced Nov. 7 that it would stop development of MDCO-216, an investigational cholesterol efflux promoter. The company also said it would increase its investment in PCSK9i, its investigational proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor.

Strong Impella sales growth help Abiomed increase revenue 35 percent in 2Q of 2016

Abiomed’s revenue increased 35 percent to $103 million and its GAAP net income increased to $0.20 per diluted share during the second quarter of FY2017 compared with the same time period last year.

Endologix Reports Results for the Third Quarter 2016

IRVINE, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and nine months ended September 30, 2016.

Pfizer stops clinical trial development program for PCSK9 inhibitor

After finding issues in clinical trials and assessing the current market, Pfizer Inc. announced Nov. 1 that it was discontinuing development of bococizumab, its investigational proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor.

TAVR sales increase 39% for Edwards Lifesciences during 3Q

During the third quarter of 2016, Edwards Lifesciences’ revenue increased 20.1 percent to $739.4 million and its GAAP earnings per share increased 20.4 percent to $0.65 per share compared with the same time period last year. Meanwhile, adjusted earnings per share increased 25.9 percent to $0.68 per share.

Pediatric interventional cardiology market anticipates 9 percent growth by 2022

Advancements in technology are driving market growth.

Thumbnail

Conferencing with the Cardiologist: Virtual Visits Bring Patients + Providers Together Between Scheduled Appointments

Cardiologists are leveraging telemedicine to be in two places at once.

Thumbnail

Give + Take: Pharma, Payers Forge Risk-sharing Deals for New Heart Drugs

Performance-based risk-sharing deals allow payers to hedge their bets with new drugs while helping pharmaceutical companies grow market share.

Displaying 1761 - 1768 of 2350

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.